Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway
The Biotechnology Centre, University of Oslo, Oslo, Norway
MAC (UK) Neuroscience Ltd, Manchester, United Kingdom
MAC (UK) Neruoscience Ltd, Liverpool, United Kingdom
Singapore General Hospital, Singapore, Singapore
Department of Orthopedic Surgery, Bad Abbach, Bavaria, Germany
Shaare Zedek Medical Center, Jerusalem, Israel
Hospital General of Mostoles, Madrid, Spain
Central Hospital of Asturias, Oviedo, Asturias, Spain
Sant Rafael Hospital, Barcelona, Spain
Bergmannsheil department of pain therapy, Bochum, Nordrhein-Westfalen, Germany
Northumbria Healthcare NHS Foundation Trust, North Shields, Tyne And Wear, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.